Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV
Mahmoud M. Shehata,
Ahmed Mostafa,
Lisa Teubner,
Sara H. Mahmoud,
Ahmed Kandeil,
Rabeh Elshesheny,
Thamer A. Boubak,
Renate Frantz,
Luigi La Pietra,
Stephan Pleschka,
Ahmed Osman,
Ghazi Kayali,
Trinad Chakraborty,
Mohamed A. Ali,
Mobarak Abu Mraheil
Affiliations
Mahmoud M. Shehata
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Ahmed Mostafa
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Lisa Teubner
Institute of Medical Microbiology, German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen Site, Justus-Liebig University Giessen, 35392 Giessen, Germany
Sara H. Mahmoud
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Ahmed Kandeil
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Rabeh Elshesheny
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Thamer A. Boubak
Biological Department, Faculty of Science, King Abdul Aziz University, Jeddah 80203, Saudi Arabia
Renate Frantz
Institute of Medical Microbiology, German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen Site, Justus-Liebig University Giessen, 35392 Giessen, Germany
Luigi La Pietra
Institute of Medical Microbiology, German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen Site, Justus-Liebig University Giessen, 35392 Giessen, Germany
Stephan Pleschka
Institute of Medical Virology, Justus-Liebig University Giessen, 35392 Giessen, Germany
Ahmed Osman
Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo 38105, Egypt
Ghazi Kayali
Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA
Trinad Chakraborty
Institute of Medical Microbiology, German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen Site, Justus-Liebig University Giessen, 35392 Giessen, Germany
Mohamed A. Ali
Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Cairo 12622, Egypt
Mobarak Abu Mraheil
Institute of Medical Microbiology, German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen Site, Justus-Liebig University Giessen, 35392 Giessen, Germany
Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290−650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.